ROCKET PHARMACEUTICALS INC (RCKT) Fundamental Analysis & Valuation

NASDAQ:RCKT • US77313F1066

Current stock price

4.64 USD
+0.37 (+8.67%)
Last:

This RCKT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RCKT Profitability Analysis

1.1 Basic Checks

  • RCKT had negative earnings in the past year.
  • In the past year RCKT has reported a negative cash flow from operations.
  • RCKT had negative earnings in each of the past 5 years.
  • In the past 5 years RCKT always reported negative operating cash flow.
RCKT Yearly Net Income VS EBIT VS OCF VS FCFRCKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • RCKT has a Return On Assets of -67.52%. This is in the lower half of the industry: RCKT underperforms 62.43% of its industry peers.
  • With a Return On Equity value of -80.49%, RCKT perfoms like the industry average, outperforming 49.71% of the companies in the same industry.
Industry RankSector Rank
ROA -67.52%
ROE -80.49%
ROIC N/A
ROA(3y)-53.31%
ROA(5y)-46.83%
ROE(3y)-62.07%
ROE(5y)-53.74%
ROIC(3y)N/A
ROIC(5y)N/A
RCKT Yearly ROA, ROE, ROICRCKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RCKT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCKT Yearly Profit, Operating, Gross MarginsRCKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. RCKT Health Analysis

2.1 Basic Checks

  • RCKT has more shares outstanding than it did 1 year ago.
  • RCKT has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, RCKT has a worse debt to assets ratio.
RCKT Yearly Shares OutstandingRCKT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
RCKT Yearly Total Debt VS Total AssetsRCKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • RCKT has an Altman-Z score of -2.57. This is a bad value and indicates that RCKT is not financially healthy and even has some risk of bankruptcy.
  • RCKT has a Altman-Z score (-2.57) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.07 indicates that RCKT is not too dependend on debt financing.
  • RCKT has a worse Debt to Equity ratio (0.07) than 60.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -2.57
ROIC/WACCN/A
WACCN/A
RCKT Yearly LT Debt VS Equity VS FCFRCKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • RCKT has a Current Ratio of 6.38. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
  • RCKT has a better Current ratio (6.38) than 63.97% of its industry peers.
  • RCKT has a Quick Ratio of 6.38. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of RCKT (6.38) is better than 64.93% of its industry peers.
Industry RankSector Rank
Current Ratio 6.38
Quick Ratio 6.38
RCKT Yearly Current Assets VS Current LiabilitesRCKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. RCKT Growth Analysis

3.1 Past

  • RCKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.47%, which is quite impressive.
EPS 1Y (TTM)27.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.62% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.6%
EPS Next 2Y17.02%
EPS Next 3Y15.18%
EPS Next 5Y14.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. RCKT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RCKT. In the last year negative earnings were reported.
  • Also next year RCKT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCKT Price Earnings VS Forward Price EarningsRCKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCKT Per share dataRCKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • RCKT's earnings are expected to grow with 15.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.02%
EPS Next 3Y15.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RCKT Dividend Analysis

5.1 Amount

  • No dividends for RCKT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RCKT Fundamentals: All Metrics, Ratios and Statistics

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (3/25/2026, 3:17:10 PM)

4.64

+0.37 (+8.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners85.93%
Inst Owner Change-0.66%
Ins Owners4.15%
Ins Owner Change27.25%
Market Cap503.76M
Revenue(TTM)N/A
Net Income(TTM)-223.12M
Analysts74.29
Price Target7.86 (69.4%)
Short Float %13.51%
Short Ratio5.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.23%
Min EPS beat(2)12.64%
Max EPS beat(2)17.82%
EPS beat(4)3
Avg EPS beat(4)9.28%
Min EPS beat(4)-3.91%
Max EPS beat(4)17.82%
EPS beat(8)6
Avg EPS beat(8)8.08%
EPS beat(12)9
Avg EPS beat(12)9.01%
EPS beat(16)10
Avg EPS beat(16)4.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.12%
EPS NQ rev (1m)8.1%
EPS NQ rev (3m)8.1%
EPS NY rev (1m)-0.48%
EPS NY rev (3m)2.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)5.42%
Revenue NY rev (3m)-0.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.82
P/tB 2.37
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-1.75
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0
BVpS2.55
TBVpS1.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.52%
ROE -80.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.31%
ROA(5y)-46.83%
ROE(3y)-62.07%
ROE(5y)-53.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.38
Quick Ratio 6.38
Altman-Z -2.57
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)99.53%
Cap/Depr(5y)115.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.71%
EPS Next Y21.6%
EPS Next 2Y17.02%
EPS Next 3Y15.18%
EPS Next 5Y14.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.35%
EBIT Next 3Y6.25%
EBIT Next 5YN/A
FCF growth 1Y11.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.4%
OCF growth 3YN/A
OCF growth 5YN/A

ROCKET PHARMACEUTICALS INC / RCKT Fundamental Analysis FAQ

What is the fundamental rating for RCKT stock?

ChartMill assigns a fundamental rating of 1 / 10 to RCKT.


Can you provide the valuation status for ROCKET PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ROCKET PHARMACEUTICALS INC (RCKT). This can be considered as Overvalued.


How profitable is ROCKET PHARMACEUTICALS INC (RCKT) stock?

ROCKET PHARMACEUTICALS INC (RCKT) has a profitability rating of 0 / 10.


What is the expected EPS growth for ROCKET PHARMACEUTICALS INC (RCKT) stock?

The Earnings per Share (EPS) of ROCKET PHARMACEUTICALS INC (RCKT) is expected to grow by 21.6% in the next year.